CervoMed announced the appointment of William Elder as Chief Financial Officer, effective June 1, 2024. Elder will continue to serve as General Counsel and Corporate Secretary. He will succeed William Tanner who has served as Chief Financial Officer to CervoMed and its predecessor, EIP Pharma, since September 2022. Tanner will continue as a consultant to CervoMed following the transition. Elder has served as the Company’s General Counsel and Corporate Secretary since September 2020 and as the Company’s Acting Principal Financial Officer since March 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
- CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
- CervoMed reports Q1 EPS (41c) vs ($1.03) last year
- CervoMed files to sell 5.06M shraes of common stock for holders
- CervoMed Updates Stakeholders on Clinical and Financial Status
- CervoMed price target raised to $65 from $50 at Canaccord